Clinical Scorecard: Long-term Outcomes of Adult Liver Transplant Recipients: Insights from 40 Years at a Single Institution
At a Glance
Category
Detail
Condition
End-stage liver diseases and hepatic tumors requiring liver transplantation
Key Mechanisms
Liver transplantation as a curative therapy involving surgical replacement of diseased liver with donor liver; immunosuppression to prevent graft rejection
Target Population
Adult patients undergoing liver transplantation at a single institution from 1982 to 2012
Care Setting
Tertiary care hospital specialized in liver transplantation (Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome)
Key Highlights
Liver transplantation is the gold-standard treatment for acute and chronic liver diseases and hepatic tumors.
Five- and ten-year post-transplant survival rates have improved to approximately 70–75% and 50–60%, respectively.
Long-term survival analysis (>10 years) is limited but critical to identify factors influencing outcomes.
Guideline-Based Recommendations
Diagnosis
Assess liver disease severity using UNOS status and Child–Pugh score for transplant candidacy.
Exclude pediatric patients and combined organ transplants for adult LT outcome studies.
Management
Use immunosuppressive induction (steroids, immunoglobulins) and maintenance therapies (cyclosporine, tacrolimus, mTor inhibitors, azathioprine, mycophenolic acid derivatives).
Optimize surgical techniques including caval reconstruction and minimize ischemia time.
Exclude donation after circulatory death and living donor transplants in outcome analyses.
Monitoring & Follow-up
Follow patients longitudinally with survival censored at last follow-up date.
Monitor for primary non-function (PNF) and primary dysfunction (PDF) within defined post-transplant time frames.
Use prospective databases and apply STROBE guidelines for observational study reporting.
Risks
Primary non-function leading to retransplantation or death within 7 days post-LT.
Primary dysfunction causing retransplantation or death after 7 days without other causes.
Factors limiting long-term survival require identification via multivariable logistic regression.
Patient & Prescribing Data
Adult liver transplant recipients from a single center over 30 years, excluding pediatric, combined, living donor, and DCD transplants.
Immunosuppressive regimens tailored with induction and maintenance drugs; survival outcomes improved over decades with advances in surgical and medical management.
Clinical Best Practices
Careful patient selection based on UNOS status and liver disease severity.
Standardized immunosuppression protocols to balance rejection risk and drug toxicity.
Meticulous surgical technique to reduce ischemia time and complications.
Long-term follow-up and data collection to identify predictors of survival beyond 10 years.
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
